HC Wainwright & Co. Maintains Buy on Trevi Therapeutics, Raises Price Target to $24
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Brandon Folkes maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $24.
HC Wainwright & Co. analyst Brandon Folkes maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $24.